Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Olema Pharmaceuticals, Inc. (OLMA) · filed Sep 14, 2023

Accession no.
0000921895-23-002167
Filed
Sep 14, 2023, 4:25 PM ET
Trade date
Sep 12-14, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $14.8M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Director, Other: See Explanation of Responses
BVF Partners L PCIK 0001055947Director, 10% Owner
BVF IncCIK 0001056807Director, 10% Owner
Biotechnology Value Fund II LPCIK 0001102444Director, Other: See Explanation of Responses
Lampert Mark NCIK 0001233840Director, 10% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Director, Other: See Explanation of Responses
BVF Partners OS Ltd.CIK 0001660684Director, Other: See Explanation of Responses
BVF I GP LLCCIK 0001803805Director, Other: See Explanation of Responses
BVF II GP LLCCIK 0001803806Director, Other: See Explanation of Responses
BVF GP Holdings LLCCIK 0001803809Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 12, 2023Common stock, $0.0001 par valuePPurchaseAcquired+775,278$9.84+$7,628,735.524,688,954Direct
Sep 12, 2023Common stock, $0.0001 par valuePPurchaseAcquired+677,853$9.84+$6,670,073.523,584,512Direct
Sep 12, 2023Common stock, $0.0001 par valuePPurchaseAcquired+52,801$9.84+$519,561.84524,151Direct
Sep 14, 2023Common stock, $0.0001 par valueJOtherAcquired+99,556––99,556Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)